GlassScriptPhysician profile
Hema Salvady
NPI 1609962885
$25,790.23
in general payments reported to CMS, 2019-2025
48 companies · $4,591 in 2025
The $4,591 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,659 · 2020: $3,038 · 2021: $3,289 · 2022: $3,384 · 2023: $3,699 · 2024: $3,131 · 2025: $4,591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,243.00 |
| Education | $177.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,465.75 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $4,322.12 | 2019-2025 | Enbrel, Tavneos, Evenity |
| Ucb, INC. | $1,798.06 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,528.44 | 2019-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $1,497.18 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,212.82 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $1,159.13 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,003.54 | 2019-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $938.19 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $935.07 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $790.63 | 2021-2025 | Saphnelo |
| Genzyme Corporation | $644.20 | 2019-2025 | |
| Horizon Therapeutics Plc | $618.27 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $555.01 | 2021-2025 | Lupkynis |
| Welch Allyn | $520.00 | 2021 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $472.05 | 2019-2025 | Strensiq |
| Ani Pharmaceuticals, INC. | $403.91 | 2022-2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $279.73 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $275.98 | 2023-2025 | Idacio |
| Organon LLC | $213.32 | 2022-2025 | Hadlima, Renflexis |
| Sanofi-Aventis U.S. LLC | $209.51 | 2019-2025 | |
| Hikma Pharmaceuticals USA | $178.62 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $177.15 | 2019 | |
| Celgene Corporation | $176.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.46 | 2022-2024 | Cyltezo, Ofev |
| Radius Health, INC. | $147.83 | 2019-2025 | Tymlos |
| Almatica Pharma LLC | $104.41 | 2025 | Teriparatide |
| Sobi, INC | $100.65 | 2019-2025 | |
| Kyowa Kirin, INC. | $87.77 | 2024-2025 | Crysvita |
| Merck Sharp & Dohme LLC | $85.02 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $81.62 | 2020-2024 | Truxima |
| Invivyd INC | $75.72 | 2025 | Pemgarda |
| Antares Pharma, INC. | $73.61 | 2019-2020 | |
| Sandoz INC. | $65.73 | 2020-2024 | Hyrimoz |
| Fidia Pharma USA INC. | $62.09 | 2019-2024 | Hymovis |
| Medexus Pharma, INC. | $61.11 | 2019 | |
| Tersera Therapeutics LLC | $59.75 | 2024-2025 | Quzyttir |
| Gilead Sciences, INC. | $43.59 | 2020 | |
| Bioventus LLC | $28.48 | 2022 | |
| Depuy Synthes Sales INC. | $26.10 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $24.98 | 2023 | Arcalyst |
| Pacira Therapeutics, INC. | $24.84 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $22.21 | 2022 | |
| Avanos Medical | $18.69 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $18.65 | 2024 | Arcalyst |
| Celltrion USA INC. | $17.32 | 2023 | Yuflyma |
| Ibsa Pharma INC. | $14.84 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hema Salvady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.